title: Depleting intratumoral CD4+CD25+ regulatory T cells via FasL protein transfer enhances the therapeutic efficacy of adoptive T cell transfer.
abstract: One strategy for improving adoptive therapy is preconditioning the host immune environment by depleting CD4(+)CD25(+) regulatory T cells (Treg) suppressive to antitumor responses. Given that Treg increase, or selectively accumulate, within tumors and are sensitive to FasL-mediated apoptosis, we test here the hypothesis that inducing apoptosis of intratumoral Treg using FasL may improve adoptive T cell therapy. We show that FasL applied intratumorally via protein transfer decreases intratumoral Treg via inducing apoptosis in these cells. Significantly, we show that the use of FasL prior to the infusion of tumor-reactive CD8(+) T cells enhances the therapeutic efficacy of adoptive T cell transfer against established tumors, which is mediated by persistent, systemic antitumor immunity. Intratumoral FasL protein transfer also results in neutrophil infiltration of tumor. However, we show that intratumoral immunodepletion of neutrophils does not abolish the effect of FasL on adoptive transfer. Rather, the effect of FasL is completely abolished by cotransfer of Treg, isolated from the tumor-draining lymph nodes. Hence, our study shows for the first time that using FasL to predeplete intratumoral Treg provides a useful means for optimizing adoptive therapy.
authors.affiliation: Department of Biomedical Sciences, College of Medicine at Rockford, University of Illinois, 1601 Parkview Avenue, Rockford, IL 61107, USA. aoshuang@uic.edu
authors.forename: Aoshuang
authors.initials: A
authors.lastname: Chen
authors.forename: Shanrong
authors.initials: S
authors.lastname: Liu
authors.forename: David
authors.initials: D
authors.lastname: Park
authors.forename: Youmin
authors.initials: Y
authors.lastname: Kang
authors.forename: Guoxing
authors.initials: G
authors.lastname: Zheng
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000276:immunology; D053222:Fas Ligand Protein / Q000276:immunology*; D016219:Immunotherapy, Adoptive / Q000379:methods*; D053645:Interleukin-2 Receptor alpha Subunit / Q000096:biosynthesis / Q000276:immunology*; D007940:Leukemia L5178; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology; D008223:Lymphoma / Q000276:immunology* / Q000628:therapy*; D051379:Mice; D008807:Mice, Inbred BALB C; D008811:Mice, Inbred DBA; D009504:Neutrophils / Q000276:immunology; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*
chemical_list: D053222:Fas Ligand Protein; D053645:Interleukin-2 Receptor alpha Subunit